依那普利在正常受试者和肾功能损害患者中的药代动力学。
Pharmacokinetics of enalapril in normal subjects and patients with renal impairment.
作者信息
Kelly J G, Doyle G, Donohue J, Laher M, Vandenburg M J, Currie W J, Cooper W D
出版信息
Br J Clin Pharmacol. 1986 Jan;21(1):63-9. doi: 10.1111/j.1365-2125.1986.tb02823.x.
Abstract
The pharmacokinetics of enalaprilat were studied after administration of single and multiple doses of enalapril maleate to people with normal and impaired renal function. Renal impairment was associated with higher serum concentrations of enalaprilat, longer times to peak concentrations, slower decline of serum concentrations and with reduced urinary elimination. Urinary elimination of enalaprilat was closely related to renal function. In patients with severe renal impairment (GFR values below 30 ml min-1 1.73 m-2) significantly smaller doses of enalapril maleate will be required than in patients with normal or less severely impaired renal function.
摘要
在对肾功能正常和受损的人群给予单剂量和多剂量马来酸依那普利后，研究了依那普利拉的药代动力学。肾功能损害与依那普利拉的血清浓度升高、达到峰值浓度的时间延长、血清浓度下降缓慢以及尿排泄减少有关。依那普利拉的尿排泄与肾功能密切相关。与肾功能正常或轻度受损的患者相比，严重肾功能损害（肾小球滤过率值低于30 ml·min⁻¹·1.73 m⁻²）的患者所需的马来酸依那普利剂量要小得多。
相似文献
1
Pharmacokinetics of enalapril in normal subjects and patients with renal impairment.依那普利在正常受试者和肾功能损害患者中的药代动力学。
Br J Clin Pharmacol. 1986 Jan;21(1):63-9. doi: 10.1111/j.1365-2125.1986.tb02823.x.
2
The effect of renal function on enalapril kinetics.肾功能对依那普利动力学的影响。
Clin Pharmacol Ther. 1985 Dec;38(6):661-6. doi: 10.1038/clpt.1985.242.
3
Effect of hydrochlorothiazide on the pharmacokinetics of enalapril in hypertensive patients with varying renal function.
J Cardiovasc Pharmacol. 1996 Jan;27(1):7-11. doi: 10.1097/00005344-199601000-00002.
4
The pharmacokinetics of enalapril in hospitalized patients with congestive heart failure.依那普利在充血性心力衰竭住院患者中的药代动力学。
Br J Clin Pharmacol. 1987 Apr;23(4):403-10. doi: 10.1111/j.1365-2125.1987.tb03069.x.
5
Disposition of enalapril and enalaprilat in renal insufficiency.依那普利和依那普利拉在肾功能不全中的处置
Kidney Int Suppl. 1987 May;20:S117-22.
6
Pharmacokinetics of enalapril in congestive heart failure.
Drugs. 1986;32 Suppl 5:40-4. doi: 10.2165/00003495-198600325-00006.
7
Enalapril dosage in progressive chronic nephropathy: a randomised, controlled trial.依那普利治疗进展性慢性肾病的剂量：一项随机对照试验。
Eur J Clin Pharmacol. 2005 Apr;61(2):87-96. doi: 10.1007/s00228-005-0893-x. Epub 2005 Mar 11.
8
Pharmacokinetics of lisinopril, enalapril and enalaprilat in renal failure: effects of haemodialysis.赖诺普利、依那普利和依那普利拉在肾衰竭中的药代动力学：血液透析的影响。
Br J Clin Pharmacol. 1988 Dec;26(6):781-6. doi: 10.1111/j.1365-2125.1988.tb05319.x.
9
High serum enalaprilat in chronic renal failure.慢性肾衰竭患者血清依那普利拉水平升高。
J Renin Angiotensin Aldosterone Syst. 2001 Dec;2(4):240-5. doi: 10.3317/jraas.2001.038.
10
Age and the pharmacokinetics of angiotensin converting enzyme inhibitors enalapril and enalaprilat.年龄与血管紧张素转换酶抑制剂依那普利和依那普利拉的药代动力学
Br J Clin Pharmacol. 1986 Apr;21(4):341-8. doi: 10.1111/j.1365-2125.1986.tb05205.x.
引用本文的文献
1
Untargeted metabolic analysis in serum samples reveals metabolic signature in children with congenital heart failure on enalapril therapy.血清样本的非靶向代谢分析揭示了接受依那普利治疗的先天性心力衰竭儿童的代谢特征。
Front Pediatr. 2025 Apr 28;13:1530063. doi: 10.3389/fped.2025.1530063. eCollection 2025.
2
Safety of drug use in patients with a primary mitochondrial disease: An international Delphi-based consensus.原发性线粒体疾病患者药物使用的安全性：基于国际德尔菲共识的研究。
J Inherit Metab Dis. 2020 Jul;43(4):800-818. doi: 10.1002/jimd.12196. Epub 2020 Feb 7.
3
Tailored Assays for Pharmacokinetic and Pharmacodynamic Investigations of Aliskiren and Enalapril in Children: An Application in Serum, Urine, and Saliva.阿利吉仑和依那普利在儿童体内药代动力学和药效学研究的定制分析方法：在血清、尿液和唾液中的应用
J Pediatr Pharmacol Ther. 2015 Nov-Dec;20(6):431-52. doi: 10.5863/1551-6776-20.6.431.
4
Risk-benefit ratio of angiotensin antagonists versus ACE inhibitors in end-stage renal disease.血管紧张素拮抗剂与血管紧张素转换酶抑制剂在终末期肾病中的风险效益比
Drug Saf. 2000 May;22(5):350-60. doi: 10.2165/00002018-200022050-00003.
5
Comparison of the pharmacokinetics of fosinoprilat with enalaprilat and lisinopril in patients with congestive heart failure and chronic renal insufficiency.福辛普利拉与依那普利拉和赖诺普利在充血性心力衰竭和慢性肾功能不全患者中的药代动力学比较。
Br J Clin Pharmacol. 2000 Jan;49(1):23-31. doi: 10.1046/j.1365-2125.2000.00103.x.
6
Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure.血管紧张素转换酶（ACE）抑制剂在肾衰竭患者中的临床药代动力学
Clin Pharmacokinet. 1993 Mar;24(3):230-54. doi: 10.2165/00003088-199324030-00005.
7
Effect of renal function on the pharmacokinetics and pharmacodynamics of trandolapril.肾功能对群多普利药代动力学和药效学的影响。
Br J Clin Pharmacol. 1993 Feb;35(2):128-35.
8
Lisinopril in hypertensive patients with and without renal failure.
Eur J Clin Pharmacol. 1987;32(1):11-6. doi: 10.1007/BF00609951.
9
Pharmacokinetics of lisinopril, enalapril and enalaprilat in renal failure: effects of haemodialysis.赖诺普利、依那普利和依那普利拉在肾衰竭中的药代动力学：血液透析的影响。
Br J Clin Pharmacol. 1988 Dec;26(6):781-6. doi: 10.1111/j.1365-2125.1988.tb05319.x.
10
Angiotensin-converting enzyme inhibitors. Relationship between pharmacodynamics and pharmacokinetics.血管紧张素转换酶抑制剂。药效学与药代动力学之间的关系。
Clin Pharmacokinet. 1988 Nov;15(5):295-318. doi: 10.2165/00003088-198815050-00003.
本文引用的文献
1
Enalapril maleate and a lysine analogue (MK-521): disposition in man.马来酸依那普利与赖氨酸类似物（MK-521）：在人体中的处置情况
Br J Clin Pharmacol. 1982 Sep;14(3):357-62. doi: 10.1111/j.1365-2125.1982.tb01991.x.
2
3
A new class of angiotensin-converting enzyme inhibitors.一类新型的血管紧张素转换酶抑制剂。
Nature. 1980 Nov 20;288(5788):280-3. doi: 10.1038/288280a0.
4
The physiological disposition and metabolism of enalapril maleate in laboratory animals.马来酸依那普利在实验动物体内的生理处置与代谢
Drug Metab Dispos. 1982 Jan-Feb;10(1):15-9.
5
Pharmacokinetics of repeated single oral doses of enalapril maleate (MK-421) in normal volunteers.
Biopharm Drug Dispos. 1984 Jul-Sep;5(3):273-80. doi: 10.1002/bdd.2510050309.
6
Digoxin metabolism in the elderly.老年人地高辛的代谢
Circulation. 1969 Apr;39(4):449-53. doi: 10.1161/01.cir.39.4.449.
Zotero 插件